Diagenode

A Type II-B Cas9 nuclease with minimized off-targets and reduced chromosomal translocations in vivo


Bestas B. et al.

Streptococcus pyogenes Cas9 (SpCas9) and derived enzymes are widely used as genome editors, but their promiscuous nuclease activity often induces undesired mutations and chromosomal rearrangements. Several strategies for mapping off-target effects have emerged, but they suffer from limited sensitivity. To increase the detection sensitivity, we develop an off-target assessment workflow that uses Duplex Sequencing. The strategy increases sensitivity by one order of magnitude, identifying previously unknown SpCas9’s off-target mutations in the humanized PCSK9 mouse model. To reduce off-target risks, we perform a bioinformatic search and identify a high-fidelity Cas9 variant of the II-B subfamily from Parasutterella secunda (PsCas9). PsCas9 shows improved specificity as compared to SpCas9 across multiple tested sites, both in vitro and in vivo, including the PCSK9 site. In the future, while PsCas9 will offer an alternative to SpCas9 for research and clinical use, the Duplex Sequencing workflow will enable a more sensitive assessment of Cas9 editing outcomes.

Subject terms: Genetic engineering, Gene therapy, CRISPR-Cas9 genome editing

Tags
Tagmentase

Share this article

Published
September, 2023

Source

Products used in this publication

  • Tubes
    C01070010-10
    Tagmentase

       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy